Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Is the Reckitt Benckiser share price worth investigating?

Published 16/09/2019, 08:41
Updated 16/09/2019, 10:01
© Reuters.

© Reuters.

It is no secret that I like consumable company stocks, especially if the business has a stellar product range like Unilever (LON:ULVR), with items that are sold with high margins and are frequently purchased. With low-value products, people are less inclined to cut back on spending for a smaller purchase.

A consumable-type company of this kind will usually be quite defensive in nature and will often have a wide moat — brand loyalty — that tends to keep competitors at bay. You can never underestimate brand loyalty for frequently purchased items. I suspect everyone has a couple of products they wouldn’t substitute for unbranded supermarket own-goods. With this in mind, let’s take a look at Reckitt Benckiser (LSE: RB).

Reckitt Benckiser (LON:RB) has two arms of its portfolio — Hygiene Home and Health — which with the company’s plan for RB 2.0, will be two independent businesses. Its product range across both sections includes household names such as Gaviscon, Veet, Durex, Nurofen, Dettol and Harpic. With such a strong portfolio, I’m sure you would expect the stock to be trading at a high valuation. You’d be correct in thinking this. The stock is trading at a price-to-earnings ratio of approximately 18.

Fair price for a wonderful company? To me, the market seems to be valued highly at the moment. Therefore Reckitt Benckiser’s valuation seems neither magnificently cheap nor expensive. By contrast, Unilever is trading at a price-to-earnings ratio of 23. In the current conditions, to quote Warren Buffett, I would be happy to pay a fair price for a wonderful company. Does Reckitt Benckiser tick this box?

Reckitt posted flat like-for-like sales in its half-yearly results, disappointing the market, reducing its share price by 4% since the announcement was made. Despite this, the group announced a 4% increase in its interim dividend.

Over the previous five years, revenue and profit has continued to steadily increase. The company has a brilliant opportunity to grow its brand in China, with the acquisition of Mead Johnson, an infant milk formula manufacturer. However, due to the declining birth rates in China coupled with increasing competition, this has yet to pay off as much as investors would like. I believe a lot of Reckitt Benckiser’s success will be determined by the outcome of how Mead Johnson performs in the Chinese market in the future.

Looking forward With new chief executive Laxman Narasimha at the helm since the beginning of September, we can expect some changes in the long term. My colleague believes that a full split between the two arms could be on the cards. I’m inclined to agree with them, and any such split could see a surge in the share price.

I think the company’s future in the event of the UK leaving the EU without a deal would be OK. With Reckitt Benckiser’s global presence, I believe the company is well-positioned for any Brexit scenario.

The company is sure to undergo some changes in the future. If some of these changes go ahead as predicated, I think value could be added for shareholders.

T Sligo has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Motley Fool UK 2019

First published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.